Edwards Lifesciences (EW) Stock Statistics & Valuation Metrics

Edwards Lifesciences has a market cap or net worth of $39.24B. The enterprise value is CHF42.41B.

Edwards Lifesciences has 587,100,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Edwards Lifesciences’s return on equity (ROE) is 0.42 and return on invested capital (ROIC) is 10.72%.

The current PE Ratio of Edwards Lifesciences is 34.3. Edwards Lifesciences’s PEG ratio is 0.05.

In the last 12 months, Edwards Lifesciences had revenue of 5.44B and earned 4.17B in profits. Earnings per share was 6.98.

In the last 12 months, operating cash flow was 1.02B and capital expenditures -212.60M, giving a free cash flow of 804.20M billion.

Edwards Lifesciences pays an annual dividend of ―, resulting in a dividend yield of ―

Edwards Lifesciences upcoming earnings date is Feb 4, 2026, After Close (Confirmed).

Edwards Lifesciences as a current ratio of 4.18, with Debt / Equity ratio of 6.86%

In the past 12 months, Edwards Lifesciences has paid 152.10M in taxes.

Edwards Lifesciences EV to EBITDA ratio is 24.32, with an EV/FCF ratio of 144.54.

Edwards Lifesciences has $3.84B in cash and marketable securities with $700.30M in debt, giving a net cash position of $3.14B billion.

Gross margin is 78.25%, with operating margin of 25.35%, and net profit margin of 76.75%.

The average price target for Edwards Lifesciences is $74.73, which is 11.43% higher than the current price. The consensus rating is Moderate Buy